US Patent Issued to Ascentage Pharma (Suzhou), Ascentage Pharma Group on April 29 for "Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway" (Chinese Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,287,338, issued on April 29, was assigned to Ascentage Pharma (Suzhou) Co. Ltd. (Jiangsu, China) and Ascentage Pharma Group Corp Ltd. (Hong Kong).

"Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway" was invented by Yifan Zhai (Jiangsu, China), Dajun Yang (Jiangsu, China), Douglas Dong Fang (Jiangsu, China) and Ran Tao (Jiangsu, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are biomarkers for predicting the efficacy of MDM2 inhibitor or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor in treating cancer patients. Also provided are compositions, e.g., kits, for evaluating...